Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. reports that Chief Financial Officer Philippe Sauvage exercised employee stock options covering 40,000 shares of Class A common stock on July 15, 2026 through two transactions at exercise prices of $1.97 and $2.17 per share. Corresponding option positions were reduced, while the acquired shares are held directly. Footnotes state that the reported common share balance includes 1,458 shares purchased through the employee stock purchase plan on May 19, 2026, and describe option grants that vest 25% on the one-year anniversaries of October 7, 2024 and February 28, 2025 and monthly over the following 36 months, subject to continued service.
Nuvation Bio Inc. has fully closed a registered underwritten offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including a $37.5 million greenshoe exercised by underwriters.
The company expects net proceeds of about $277.6 million after fees. It used roughly $2.2 million of the greenshoe proceeds to purchase additional capped call transactions designed to lessen potential dilution or higher cash payments upon note conversion, and plans to deploy the remaining funds for general corporate purposes such as working capital, operating expenses, capital expenditures, and administrative costs.
Nuvation Bio Inc. completed an underwritten public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with underwriters holding a 30‑day option to buy up to an additional $37.5 million of notes. The notes are unsecured, pay interest semiannually, and are convertible into cash, Class A common stock, or a combination, at the company’s election.
The initial conversion rate is 127.4941 shares per $1,000 of notes, implying a conversion price of about $7.84 per share, a 35.0% premium to the June 25, 2026 share price. Nuvation Bio estimates net proceeds of $241.2 million, used to fund $14.9 million of capped call transactions and to repay in full about $58.5 million under its senior secured loan agreement, with the balance for general corporate purposes.
Nuvation Bio is offering $250,000,000 aggregate principal amount of 0.75% Convertible Senior Notes due 2032. The notes bear interest at 0.75% per year, mature on July 1, 2032, and are convertible at an initial rate of 127.4941 shares per $1,000 (≈ $7.84 per share), subject to adjustment and conditional conversion mechanics.
The company expects net proceeds of approximately $241.2 million, intends to use proceeds to pay the $14.9 million capped call cost, repay in full the Loan Agreement obligations and for general corporate purposes, and will issue the notes in book-entry form with expected delivery around June 30, 2026.
Nuvation Bio Inc. proposes an offering of $200,000,000 principal amount of % Convertible Senior Notes due 2032. The notes bear cash interest payable semiannually, may be convertible into Class A common stock at an initial conversion rate (conversion price disclosed in the prospectus), and mature on July 1, 2032. Prior to April 1, 2032, conversions are conditional; after that date conversions are permitted at any time. The company may redeem the notes on or after July 6, 2029 if the Class A common stock trading thresholds are met. Net proceeds are expected to be used to pay capped call costs, repay the Loan Agreement and for general corporate purposes.
Nuvation Bio Inc. chief people officer Stacy Markel exercised stock options and sold shares in the company. On June 23, 2026, Markel exercised options for 34,620 shares at $1.74 per share and 90,380 shares at $1.87 per share, then sold 125,000 Class A common shares in an open-market transaction at a weighted-average price of $6.0255 per share, with trades ranging from $6.00 to $6.085, under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Markel directly holds 32,591 Class A common shares.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options and sold shares in the company. Wentworth exercised options to acquire 63,000 shares of Class A common stock at an exercise price of $2.93 per share, then sold 63,000 shares in an open-market transaction at a weighted-average price of $6.0189 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, Wentworth directly holds 53,000 shares of Class A common stock.
Nuvation Bio Inc. Chief Financial Officer Philippe Sauvage exercised stock options and sold shares in a coordinated transaction. He exercised options to acquire 47,668 shares of Class A common stock at $2.17 per share, then sold 47,668 shares in open-market trades at a weighted-average price of $6.0076 per share under a Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, he directly holds 12,673 shares of Class A common stock.
NUVB trading reported via a Form 144: 63,000 shares of Common stock are listed to be sold on 06/23/2026 following an exercise of stock options for cash. The filing also records prior 10b5-1 sales of 36,750 shares on 04/17/2026 and 200,000 shares on 04/06/2026.